These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17289744)

  • 1. Effect of hypertension on anticoagulated patients with atrial fibrillation.
    Lip GY; Frison L; Grind M;
    Eur Heart J; 2007 Mar; 28(6):752-9. PubMed ID: 17289744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation.
    Lip GY; Frison L; Grind M;
    J Intern Med; 2008 Jul; 264(1):50-61. PubMed ID: 18266660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
    Halperin JL;
    Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
    Albers GW;
    Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.
    Lip GY; Frison L; Halperin JL; Lane DA
    J Am Coll Cardiol; 2011 Jan; 57(2):173-80. PubMed ID: 21111555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
    Diener HC;
    Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing stroke in atrial fibrillation: the SPORTIF programme.
    Lip GY
    Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():25-30. PubMed ID: 15812201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data.
    Gjesdal K; Feyzi J; Olsson SB
    Heart; 2008 Feb; 94(2):191-6. PubMed ID: 17483128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation.
    Lip GY; Frison L; Grind M
    J Intern Med; 2007 Jun; 261(6):577-86. PubMed ID: 17547713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
    Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB; Halperin JL
    Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.
    White HD; Gruber M; Feyzi J; Kaatz S; Tse HF; Husted S; Albers GW
    Arch Intern Med; 2007 Feb; 167(3):239-45. PubMed ID: 17296878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
    Halperin JL
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ximelagatran for stroke prevention in atrial fibrillation.
    Boos CJ; Lip GY
    Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):551-63. PubMed ID: 16076267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.
    Akins PT; Feldman HA; Zoble RG; Newman D; Spitzer SG; Diener HC; Albers GW
    Stroke; 2007 Mar; 38(3):874-80. PubMed ID: 17255547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New perspectives for anticoagulation in non-rheumatic atrial fibrillation: oral antithrombins].
    Scardi S; Giansante C
    Ital Heart J Suppl; 2004 Sep; 5(9):705-11. PubMed ID: 15568608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range Observations from the SPORTIF Trials.
    Proietti M; Lip GY
    Am J Med; 2016 Oct; 129(10):1110-6. PubMed ID: 27086494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [SPORTIF III and V trials: a major breakthrough for long-term oral anticoagulation].
    Kulbertus H
    Rev Med Liege; 2003 Dec; 58(12):770-3. PubMed ID: 14978854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.